A new blood-stage malaria vaccine, RH5.1/Matrix-M, shows promising Phase IIb trial results. The vaccine is safe, highly immunogenic, and effective against malaria, offering a secondary defense alongside existing vaccines. Its 55% efficacy against clinical malaria and 80% efficacy in reducing high parasite levels highlight its potential to combat this widespread disease.
